Prognostic Markers in Pancreatic Cancer
Author Information
Author(s): Smith R A, Tang J, Tudur-Smith C, Neoptolemos J P, Ghaneh P
Primary Institution: University of Liverpool
Hypothesis
The study aims to evaluate the prognostic value of various immunohistochemical markers in resected pancreatic cancer.
Conclusion
The study concludes that vascular endothelial growth factor (VEGF) is a significant marker of adverse prognosis in resected pancreatic cancer.
Supporting Evidence
- VEGF was identified as the most informative prognostic marker with a hazard ratio of 1.51.
- Bcl-2 and bax also showed significant associations with survival.
- p53, smad4, and EGFR did not demonstrate significant prognostic value.
Takeaway
This study looked at different markers in pancreatic cancer to see which ones could help predict how patients would do after surgery. It found that a marker called VEGF is really important for understanding patient outcomes.
Methodology
The study conducted a systematic review and meta-analysis of literature evaluating various immunohistochemical markers in resected pancreatic adenocarcinoma, focusing on overall survival.
Potential Biases
There is a risk of publication bias as only studies with significant results may be more likely to be published.
Limitations
The study is limited by the retrospective nature of the included studies and variability in patient selection and methodology.
Participant Demographics
The studies included a total of 767 patients with varying demographics, but specific details on age and gender were not uniformly reported.
Statistical Information
P-Value
0.01
Confidence Interval
1.18–1.92
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website